Trial
NCT01403064
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
CSL Behring
Collaborators
—
Condition
Oral Mucositis
Intervention
ALD518
Why stopped
due to lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-11